LNTH

Lantheus Holdings Inc

Add to Watchlist

Advanced Chart

53.690

-3.54(-6.186%)1D

Line

Candle

YTD

High

62.000

Open

61.100

VWAP

55.91

Vol

2.69M

Mkt Cap

3.65B

Low

53.355

Amount

150.20M

EV/EBITDA(TTM)

7.51

Total Shares

69.31M

3.76B

EV/OCF(TTM)

7.14

P/S(TTM)

2.67

Lantheus Holdings, Inc. is a radiopharmaceutical-focused company engaged in delivering science to enable clinicians to find, fight and follow diseases to deliver patient outcomes. The Company classifies its products in three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships. Radiopharmaceutical Oncology diagnostics and therapeutics help healthcare professionals (HCPs) find, fight and follow cancer, with a focus on prostate cancer. Precision Diagnostic products assist HCPs to find and follow diseases, with a focus on cardiology. Strategic Partnerships focus on enabling precision medicine through the use of biomarker solutions, digital solutions, and radiotherapeutic platforms. Its commercial products include PYLARIFY, DEFINITY, TechneLite, Neuraceq, and others. Its clinical candidates include LNTH-2404, NAV-4694, and PNT2002, among others. The Neuraceq (florbetaben F18 injection) is an F-18 PET imaging agent for Alzheimer’s disease.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

350.53M

-5.97%

1.170

-23.53%

367.85M

-5.95%

1.247

-21.58%

364.46M

-3.77%

1.267

-25.48%

Estimates Revision

The market is revising Downward the revenue expectations for Lantheus Holdings, Inc. (LNTH) for FY2025, with the revenue forecasts being adjusted by -5.26% over the past three months. During the same period, the stock price has changed by 3.51%.

Revenue Estimates for FY2025

Revise Downward

-5.26%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-13.92%

In Past 3 Month

Stock Price

Go Up

+3.51%

In Past 3 Month

9 Analyst Rating

Wall Street analysts forecast LNTH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LNTH is 79.00 USD with a low forecast of 70.00 USD and a high forecast of 99.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

3 Hold

0 Sell

Moderate Buy

Current: 53.690

Low

70.00

Averages

79.00

High

99.00

Current: 53.690

Low

70.00

Averages

79.00

High

99.00

B. Riley

Buy

downgrade

$109 -> $84

2025-09-16

Reason

B. Riley

Price Target

$109 -> $84

2025-09-16

downgrade

Buy

Reason

B. Riley lowered the firm's price target on Lantheus to $84 from $109 and keeps a Buy rating on the shares. The firm views the near-term risk for Lantheus as whether Pylarify further loses market share and that Pylarify will be surpassed by Illuccix/Gozellix before 2nd-generation Pylarify receives pass-through status in the second half of 2026, the analyst tells investors in a research note. The firm waits for a stabilization of the stock price and better visibility into the long-term growth prospects in the next 6-12 months.

TD Cowen

Buy

downgrade

$95 -> $80

2025-09-15

Reason

TD Cowen

Price Target

$95 -> $80

2025-09-15

downgrade

Buy

Reason

TD Cowen lowered the firm's price target on Lantheus to $80 from $95 and keeps a Buy rating on the shares. The firm lowered our Pylarify pricing assumptions for 2025-2026, which should begin to recover in 2027 upon potential approval of the new formulation. They also increased their OpEx estimates, resulting in decreased 2025 EPS that is consistent with the company's guidance.

Truist

Richard Newitter

Buy

Hold

downgrade

$111 -> $63

2025-08-11

Reason

Truist

Richard Newitter

Price Target

$111 -> $63

2025-08-11

downgrade

Buy

Hold

Reason

Truist analyst Richard Newitter downgraded Lantheus to Hold from Buy with a price target of $63, down from $111.

Truist

Buy

Hold

downgrade

$111 -> $63

2025-08-11

Reason

Truist

Price Target

$111 -> $63

2025-08-11

downgrade

Buy

Hold

Reason

As previously reported, Truist downgraded Lantheus to Hold from Buy with a price target of $63, down from $111. While the firm "appreciates" the stock's selloff reflects "a lot of Pylarify uncertainty already," it thinks the multiple is going to be linked to Pylarify trends and it sees year-over-year and quarter-over-quarter deceleration as now on tap for "at least" another two quarters. While the firm still sees "underappreciated value" to the long-term pipeline, it believes shares could "mark time" for the next six months or so until there is more certainty that the second half is the bottom for Pylarify after two quarters of misses and lowering linked to it.

Citizens JMP

Outperform

maintain

$112 -> $73

2025-08-07

Reason

Citizens JMP

Price Target

$112 -> $73

2025-08-07

maintain

Outperform

Reason

Citizens JMP lowered the firm's price target on Lantheus to $73 from $112 and keeps an Outperform rating on the shares following the Q2 report. The firm attributes the Q2 miss and guidance cut to the impact of competitor Blue Earth's pricing strategy taking a bigger toll on Pylarify's business. Despite this, domestic volumes still grew 2% year-over-year, the analyst tells investors in a research note. Citizens remains encouraged about Lantheus' royalty opportunities including Flyrcado and Pylclari.

Mizuho

Outperform -> NULL

downgrade

$120 -> $70

2025-08-07

Reason

Mizuho

Price Target

$120 -> $70

2025-08-07

downgrade

Outperform -> NULL

Reason

Mizuho lowered the firm's price target on Lantheus to $70 from $120 and keeps an Outperform rating on the shares post the Q2 report. The firm says Pylarify competitive headwinds create uncertainty for the company's outlook. It sees Pylarify pressures extending into next year.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Lantheus Holdings Inc (LNTH.O) is 11.54, compared to its 5-year average forward P/E of 20.56. For a more detailed relative valuation and DCF analysis to assess Lantheus Holdings Inc 's fair value, click here.

Forward PE
Forward EV/EBITDA
Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

20.56

Current PE

11.54

Overvalued PE

34.10

Undervalued PE

7.02

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

10.59

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

14.84

Undervalued EV/EBITDA

6.35

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.11

Current PS

57.23

Overvalued PS

8.21

Undervalued PS

-0.00

Financials

Annual

Quarterly

FY2025Q3

YoY :

+1.39%

384.01M

Total Revenue

FY2025Q3

YoY :

-67.39%

43.62M

Operating Profit

FY2025Q3

YoY :

-78.82%

27.77M

Net Income after Tax

FY2025Q3

YoY :

-77.09%

0.41

EPS - Diluted

FY2025Q3

YoY :

-40.55%

94.67M

Free Cash Flow

FY2025Q3

YoY :

-9.42%

57.91

Gross Profit Margin - %

FY2025Q3

YoY :

+7.23%

27.13

FCF Margin - %

FY2025Q3

YoY :

-79.11%

7.23

Net Margin - %

FY2025Q3

YoY :

-64.02%

10.59

ROIC

Trading Trends

Insider
Hedge Fund
Congress Trading

Insider

Insiders areSelling! The selling amount has increased 5211.12% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

389.8M

USD

6-9

Months

6.2M

USD

0-12

Months

94.8K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 2127.26% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

381.5K

Volume

0-12

Months

17.1K

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

0.0

Volume

Months

0-12

205.0K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

32.0K

USD

Months

Insider

Insiders areSelling! The selling amount has increased 5211.12% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

389.8M

USD

6-9

Months

6.2M

USD

0-12

Months

94.8K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

LNTH News & Events

Events Timeline

2025-11-06 (ET)

2025-11-06

07:59:19

Lantheus CEO Markison to Retire; Heino Named Interim Successor

2025-11-06

07:34:21

Lantheus revises FY25 adjusted EPS forecast to a range of $5.50-$5.65, down from $5.50-$5.70

2025-11-06

07:32:48

Lantheus announces Q3 adjusted EPS of $1.27, matching consensus expectations.

News

7.0

11-06Globenewswire

PinnedSHAREHOLDER NOTICE: Bernstein Liebhard LLP Initiates Class Action Lawsuit for Securities Fraud Against Lantheus Holdings, Inc. (NASDAQ: LNTH)

7.0

11-06SeekingAlpha

Lantheus Refines 2025 Revenue Forecast to $1.49B-$1.51B and Indicates Leadership Change with Emphasis on PSMA PET Franchise

7.0

11-06Globenewswire

Lantheus Holdings, Inc. Class Action Update: Levi & Korsinsky Alerts Investors of Upcoming Lawsuit with Lead Plaintiff Deadline Set for November 10, 2025 – LNTH